Published Date : 03 May 2023
The global immunohistochemistry industry revenue will gain around USD 4.5 billion by 2032 from USD 2.4 billion in 2022 and is growing at a remarkable CAGR of 6.49% from 2023 to 2032.
Due to the approval of more goods and the introduction of highly advanced immunohistochemistry solutions for disease detection, the industry for these products is growing.
Immunohistochemistry is a method for identifying the presence and concentration of particular biological proteins. IHC analyzes protein expression by binding to the target proteins with specifically marked antibodies. The tumor's natural components are combined with the antibody. Only the antibodies still tied to their protein targets will remain after the combination has been rinsed after a predetermined period. The material can be examined under a microscope to determine whether antibodies are present because regions with bound antibodies will have a distinct color from regions without antibodies. More protein in the sample will attach more antibodies, giving it a deeper appearance.
Because of this, the test can determine not only whether a protein is present but also its proportional concentration. The intensity of the spotting and the proportion of stained cells determine the findings of the test. IHC methods are increasingly being used in clinical pathology, especially in the areas of hematopathology, neuropathology, and oncologic pathology. The technique has had a big impact on cancer diagnosis. As a result, it is expected that the increasing prevalence of cancer will increase the demand for immunohistochemistry and propel industry growth.
Due to the existence of key players, the high incidence of cancer and other chronic illnesses in the area, and the developed healthcare infrastructure, North America is anticipated to hold a sizable industry position throughout the projection period. For instance, the American Heart Association 2021 magazine reports that by the year 2035, it is predicted that more than 130 million people in the United States will have some form of heart disease. Similarly to this, according to Statistics Canada's 2022 report, a projected 233.9 thousand Canadians are anticipated to receive a cancer diagnosis. The industry for efficient diagnostic tools to receive appropriate therapy for heart disease and cancer is anticipated to expand as a result of the rising demand for these tools.
Asia Pacific is expected to have the quickest CAGR during the projection timeframe. Most of this can be attributed to the expanded geographic influence of international players in Asian industry places. A large patient population in countries like China and India also provides a large number of clinical patients for IHC R&D studies, which increases revenue. The demand for antibodies in the scientific study increased as a consequence of advancements in the biotechnology sector. Better government funding for biotechnology research and the rise of China and India as significant centers for clinical research both contribute to the development of the immunochemistry industry in the region. The abundance of infrastructure sites and low-cost labor is driving the growth of the clinical research organization (CRO) industry.
Immunohistochemistry Industry Report Scope:
|Market Revenue in 2023||USD 2.56 Billion|
|Projected Forecast Revenue in 2032||USD 4.5 Billion|
|Growth Rate from 2023 to 2032||CAGR of 6.49%|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2023 to 2032|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America and Middle East & Africa|
Drivers: Technological advancements drive the industry
Due to two significant technological advancements and the use of particular antibodies against different antigens, immunohistochemistry has recently emerged as a pathologist's go-to option. To characterize infectious organisms in immunohistochemistry, monoclonal or polyclonal antibodies are applied to viral, bacterial, or fungal antigens. This method is now frequently used in the diagnosis of many infectious illnesses. Immunohistochemistry, like any other diagnostic technique, needs quality control, repeatability, and specificity to find a specific infectious agent.
Therefore, several variables must be taken into consideration, particularly tissue fixation, tissue processing, and antigen retrieval, to prevent changes in immunostaining and to keep the immunoreactivity of some antigens. The use of IHC in identifying several neurodegenerative diseases brought on by numerous variables, such as cannabidiol use and cigarette smoking, is also expected to support the industry's development rate.
Restraints: Insufficient knowledge among the workforce
Immunohistochemistry and pathology services are in high demand for therapeutic uses as cancer is becoming more prevalent. Histopathology equipment is used for the majority of exams on cancer patients.
However, there is a serious lack of qualified staff in these labs. Only a small number of histopathologists are in training, and many are nearing retirement age. However, laboratories are under strain to handle an increasing number of specimens due to a lack of personnel. Therefore, it is anticipated that the sum of these variables will pose a challenge to the immunohistochemistry industry.
Opportunities: Targeted treatment and personalized medicines
Some of the most recent developments in the immunohistochemistry industry have improved the utility of these tests in the context of targeted treatment and personalized medicine, including multiplex and mutation-specific immunohistochemical tests. Multiplexed IHC, one of the more recent advancements in the immunohistochemistry industry, allows for multiparametric and in-depth analysis from a single tissue segment by utilizing cutting-edge mass spectrometric detection methods. Multiplexed IHC overcomes the technical challenges of the tagged fluorescence detection-based method, increasing immunohistochemistry industry income.
The industry for antibodies was controlled in 2022 as a result of the significant role that antibodies play in the detection of diseases and the testing of drugs. The antibodies are applied in hematopathology, neuropathology, and pathology, among other disciplines. During the projection period, the kits category is anticipated to expand at the highest CAGR. During the anticipated timeframe, the antibodies sector is anticipated to rule the global immunohistochemistry industry. The demand that antibodies be used in the immunohistochemistry detection of infectious diseases, cancer, and other disorders drives segmental growth.
The worldwide industry has also been segmented based on uses in the diagnostics and drug testing sectors. The diagnostics application category accounted for more than 69.5% of total revenue in 2022, and it is anticipated that it will hold the industry's top spot throughout the projection period. The segment's expansion is mainly driven by the rising frequency and prevalence of cancer. Additional factors influencing the industry share development of the sector include the prevalence of infectious illnesses and the favorable reimbursement climate for IHC studies.
In 2022, hospitals and diagnostics labs made up the biggest end-user segment of the worldwide IHC industry. The large amount of IHC tests performed in healthcare institutions was the cause of this expansion. Furthermore, because of shifts in the healthcare industry, there is a greater need for clinics with cutting-edge facilities. This is expected to result in a rise in sales income for this sector, and it is predicted that they will maintain this place throughout the projection period. The growing industry for disease diagnosis as a result of the rise in the prevalence of chronic illnesses is another significant factor that has significantly added to the segment's development in recent years.
Key Market Players:
Segments Covered in the Report:
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2637
You can place an order or ask any questions, please feel free to contact at email@example.com | +1 9197 992 333